Pharmacological treatment and vaccines in monkeypox virus: a narrative review and bibliometric analysis

Frontiers in Pharmacology

Pharmacology

Aroop Mohanty¹  Bijaya Kumar Padhi²  Keerti Bhusan Pradhan³  Abhimanyu Agrawal⁴  Anindita Pradhan⁵  Muhammad Aaqib Shamim⁵  Pradeep Dwivedi⁶  Prakisini Satapathy⁷  Alfonso J. Rodriguez-Morales⁸  Naushaba Akhtar⁹  Jawaher Alotaibi^1,10  Zainab A. Al Ismail^1,11  Ali Al Fraij^1,12  Ali A. Rabaan^1,13  Sai Dutt Veeramachaneni^1,14  Zainab Ahmed Alsoliabi^1,15  Russell Kabir^1,16  Ranjit Sah^1,17 

[1] All India Institute of Medical Sciences, Gorakhpur, India;Department of Community Medicine, School of Public Health, Postgraduate Institute of Medical Education and Research, Chandigarh, India;Department of Healthcare Management, Chitkara University, Chandigarh, India;Department of Pharmacology, All India Institute of Medical Sciences, Bathinda, India;Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, India;Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, India;Centre of Excellence for Tribal Health, All India Institute of Medical Sciences, Jodhpur, India;Department of Virology, Postgraduate Institute of Medical Education and Research, Chandigarh, India;Faculty of Health Sciences, Universidad Científica del Sur, Lima, Peru;Gilbert and Rose-Marie Chagoury School of Medicine, Lebanese American University, Beirut, Lebanon;Indian Council of Medical Research—Regional Medical Research Centre, Bhubaneswar, India;Infectious Diseases Unit, King Faisal Specialist Hospital and Research Center, Department of Medicine, Riyadh, Saudi Arabia;Long Term Care Department, Dhahran Long Term Hospital, Dhahran, Saudi Arabia;Medical Laboratories and Blood Bank Department, Jubail Health Network, Jubail, Saudi Arabia;Molecular Diagnostic Laboratory, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia;PSG College of Pharmacy, Coimbatore, India;Pharmacy Department, Qatif Central Hospital, Qatif, Saudi Arabia;School of Allied Health, Anglia Ruskin University, Essex, United Kingdom;Tribhuvan University Teaching Hospital, Institute of Medicine, Kathmandu, Nepal;Harvard Medical School, Boston, MA, United States;Dr. D. Y. Patil Medical College, Hospital and Research Centre, Dr D. Y. Patil Vidyapeeth, Pune, Maharashtra, India;

关键词: mpox infection;    antiviral;    drug;    management;    public health emergency;    tecovirimat;    cidofovir;    bibliometry;   

DOI  :  10.3389/fphar.2023.1149909

 received in 2023-01-23, accepted in 2023-04-25,  发布年份 2023

来源: Frontiers

【 摘 要 】

Mpox (earlier known as monkeypox) virus infection is a recognized public health emergency. There has been little research on the treatment options. This article reviews the specific drugs used to treat mpox virus infection and the vaccines used here. Instead of focusing on the mechanistic basis, this review narrates the practical, real-life experiences of individual patients of mpox virus disease being administered these medicines. We conducted a bibliometric analysis on the treatment of the mpox virus using data from several databases like PubMed, Scopus, and Embase. The research on this topic has grown tremendously recently but it is highly concentrated in a few countries. Cidofovir is the most studied drug. This is because it is indicated and also used off-label for several conditions. The drugs used for mpox virus infection include tecovirimat, cidofovir, brincidofovir, vaccinia immune globulin, and trifluridine. Tecovirimat is used most frequently. It is a promising option in progressive mpox disease in terms of both efficacy and safety. Brincidofovir has been associated with treatment discontinuation due to elevated hepatic enzymes. Cidofovir is also not the preferred drug, often used because of the unavailability of tecovirimat. Trifluridine is used topically as an add-on agent along with tecovirimat for ocular manifestations of mpox virus disease. No study reports individual patient data for vaccinia immune globulin. Though no vaccine is currently approved for mpox virus infection, ACAM 2000 and JYNNEOS are the vaccines being mainly considered. ACAM 2000 is capable of replicating and may cause severe adverse reactions. It is used when JYNNEOS is contraindicated. Several drugs and vaccines are under development and have been discussed alongside pragmatic aspects of mpox virus treatment and prevention. Further studies can provide more insight into the safety and efficacy of Tecovirimat in actively progressing mpox virus disease.

【 授权许可】

Unknown   
Copyright © 2023 Shamim, Satapathy, Padhi, Veeramachaneni, Akhtar, Pradhan, Agrawal, Dwivedi, Mohanty, Pradhan, Kabir, Rabaan, Alotaibi, Al Ismail, Alsoliabi, Al Fraij, Sah and Rodriguez-Morales.